NCT00569036 - Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

NeoplasmsSolid TumorsMetastases

Interventions

DRUG

BMS-754807

Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request

Trial Locations (5)

3002

Local Institution, East Melbourne

3011

Local Institution, Footscray

3050

Local Institution, Parkville

3084

Local Institution, Heidelberg

6009

Local Institution, Nedlands